PMV Pharmaceuticals (NASDAQ:PMVP) Releases Earnings Results, Misses Estimates By $1.18 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) posted its quarterly earnings results on Friday. The company reported ($1.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($1.18), MarketWatch Earnings reports.

PMV Pharmaceuticals stock opened at $32.10 on Monday. PMV Pharmaceuticals has a 52 week low of $31.50 and a 52 week high of $42.93.

In related news, major shareholder Ra Capital Management, L.P. bought 950,000 shares of the stock in a transaction on Tuesday, September 29th. The shares were purchased at an average price of $18.00 per share, with a total value of $17,100,000.00.

PMVP has been the topic of a number of recent research reports. Cowen initiated coverage on shares of PMV Pharmaceuticals in a research report on Tuesday, October 20th. They issued an “outperform” rating on the stock. Bank of America initiated coverage on shares of PMV Pharmaceuticals in a research report on Tuesday, October 20th. They issued a “buy” rating and a $42.00 price objective on the stock. Evercore ISI initiated coverage on shares of PMV Pharmaceuticals in a research report on Tuesday, October 20th. They issued an “outperform” rating on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of PMV Pharmaceuticals in a research report on Tuesday, October 20th. They issued a “neutral” rating and a $34.00 price objective on the stock.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations.

See Also: Can systematic risk be avoided?

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.